Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

• Published in: Clinical pharmacokinetics Vol. 60; no. 8; pp. 1049 - 1059
• Main Authors: Urva, Shweta, Quinlan, Tonya, Landry, John, Martin, Jennifer, Loghin, Corina
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2021; Springer Nature B.V
• Subjects: Antidiabetics; Area Under Curve; Body mass index; Creatinine; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Drug dosages; Gastric Inhibitory Polypeptide; GLP-1 receptor agonists; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Hemodialysis; Humans; Internal Medicine; Investigations; Kidney diseases; Medicine; Medicine & Public Health; Original; Original Research Article; Pharmaceutical Preparations; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Polypeptides

Background and Aims The pharmacokinetics (PK) and single-dose tolerability of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist being developed for once-weekly treatment of type 2 diabetes (T2D), weight management, and nonalcoholic steatohe...